Product Description
ZEN-3694 is a novel BETi that inhibits proliferation of several cancer cell lines, and synergizes with various anti-cancer agents. (Sourced from: https://www.zenithepigenetics.com/upload/media_element/36/01/2015-aacr-eortc-poster.pdf)
Mechanisms of Action: BET Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Zenith Epigenetics
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China, United States
Active Clinical Trial Count: 9
Highest Development Phases
Phase 2: Adenocarcinoma|Fallopian Tube Cancer|Lung Cancer|Ovarian Cancer|Peritoneal Cancer|Prostate Cancer|Small Cell Lung Cancer|Triple Negative Breast Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
HCC 21-091 | P2 |
Recruiting |
Fallopian Tube Cancer|Peritoneal Cancer|Ovarian Cancer |
2029-12-01 |
|
NCI-2020-04495 | P2 |
Recruiting |
Small Cell Lung Cancer|Prostate Cancer|Adenocarcinoma |
2027-04-30 |
|
HCC 22-142 | P1 |
Recruiting |
Ovarian Cancer |
2026-12-31 |
|
NCT05607108 | P2 |
Recruiting |
Lung Cancer |
2025-11-01 |